TPG Life Sciences Innovation

TPG Life Sciences Innovation (LSI) is a venture capital firm that partners with companies developing disruptive science, technologies, and business models to address significant unmet medical needs. The firm leverages deep scientific, clinical, and operational expertise, as well as investment experience across multiple therapeutic areas and modalities. LSI invests thematically in areas such as oncology, autoimmune and inflammatory diseases, cardiometabolic diseases, ophthalmology, rare diseases, and commercial-stage medical devices and tech-enabled services.

Established in 2023, LSI builds upon TPG's extensive healthcare experience, having invested over $30 billion across the global healthcare ecosystem since 2003. The firm's approach focuses on advancing breakthrough technologies to clinical proof-of-concept, aiming to deliver demonstrable benefits to patients. LSI is well-positioned to support companies and entrepreneurs from company creation through clinical development to commercial stages, utilizing TPG's decades of business-building experience, operating capabilities, and industry relationships to drive enduring growth and success.

In August 2024, TPG increased its Life Sciences Innovations fund to $580 million, targeting investments across the life sciences spectrum. This fund focuses on emerging life science companies, specifically aiding in advancing breakthrough technologies to clinical proof-of-concept. TPG's portfolio includes investments in companies such as Sionna Therapeutics, Santa Ana Bio, Ellodi Pharmaceuticals, Saluda Medical, MBrace Therapeutics, and Bicara Therapeutics, reflecting its commitment to supporting innovative solutions in the healthcare sector.